For quite a while, tramadol has been the go-to option for managing chronic pain. It’s frequently prescribed in various clinics and is a common item in medicine cabinets across the country.
Many healthcare professionals consider tramadol a sort of middle ground—it’s stronger than over-the-counter medications but is believed to be easier on the body compared to traditional opioids.
This perception contributed to its rapid adoption. However, a closer examination of the scientific data presents a less reassuring picture.
Tramadol in Chronic Pain Care
A comprehensive review of existing studies investigated the effectiveness of tramadol for chronic pain.
The researchers gathered findings from past studies, comparing tramadol with a placebo, which contains no active ingredients.
The goal was straightforward: Does this medication actually make a difference in how people feel, and what are the associated risks?
Why Tramadol Became So Common
Tramadol is a unique opioid that alleviates pain through multiple pathways. It’s typically prescribed for moderate to severe pain, whether it’s short-term or chronic.
This dual-action quality has led to its inclusion in various pain management guidelines. Over time, tramadol prescriptions surged, placing it among the most widely used opioids in the U.S.
This increase didn’t occur by chance; many doctors believed tramadol had a better side effect profile and a lower risk of addiction than other short-acting opioids, which made patients more comfortable using it.
What Earlier Studies Missed
Although tramadol has been the subject of prior studies, those evaluations often fell short of addressing critical questions. Many focused solely on pain reduction without considering safety, while others examined limited pain types. Significant gaps existed in the research.
To bridge these gaps, the researchers scoured medical databases for randomized clinical trials published until February 2025.
The trials involved comparisons of tramadol and placebo in individuals suffering from chronic pain, including cancer-related discomfort.
A Closer Look at the Trials
The final analysis reviewed 19 clinical trials with 6,506 participants. Five studies centered on nerve pain, nine on osteoarthritis, four on chronic low back pain, and one on fibromyalgia.
Participants had an average age of 58, ranging from 47 to 69. Most studies involved tramadol tablets, while only one evaluated a topical cream.
Treatment durations varied between 2 and 16 weeks, with follow-up periods ranging from 3 to 15 weeks—important because many side effects and long-term risks take time to emerge.
Small Relief, Big Risks
Upon reviewing all results, a clear conclusion surfaced. Tramadol did relieve pain but only minimally. The level of relief often fell short of what is considered meaningful.
While some individuals might have perceived slight improvements, these likely didn’t enhance daily functioning.
Eight trials monitored participants for serious side effects over durations of 7 to 16 weeks. In these cases, tramadol was associated with approximately double the risk of adverse effects compared to a placebo.
This elevated risk was primarily linked to cardiovascular issues, including chest pain, coronary artery disease, and congestive heart failure.
There was also an indication of higher cancer risk with tramadol use, although researchers cautioned that the short follow-up made this finding uncertain.
Common Side Effects
Across the studies, tramadol was connected to more frequent side effects like nausea, dizziness, constipation, and drowsiness.
Though these symptoms might seem mild, they can significantly impact daily life, especially for older adults.
The authors also identified issues with the studies themselves. Many outcomes had a high risk of bias, suggesting that tramadol’s benefits may have been exaggerated while its risks were downplayed.
Opioids in the Bigger Picture
The findings are situated within a broader opioid crisis. According to the study’s authors, about 60 million people globally experience the addictive effects of opioids.
“In 2019, drug use caused around 600,000 deaths, with nearly 80% linked to opioids and about 25% due to opioid overdoses,” the researchers noted.
“In the United States, opioid-related overdose deaths rose from 49,860 in 2019 to 81,806 in 2022.”
“Given these trends and our findings, the use of tramadol and similar opioids should be minimized as much as possible.”
Tramadol and Chronic Pain Relief
After evaluating the evidence, the research team concluded plainly. Tramadol may offer some minor relief from chronic pain, but it likely also heightens the risk of both serious and less severe side effects.
“The potential harms of tramadol for pain management likely outweigh its modest benefits,” the researchers stated.
This conclusion holds significant implications for a medication that’s widely used and trusted. It suggests that tramadol’s role in chronic pain treatment warrants serious reevaluation—not because it’s ineffective, but because its benefits might not justify the associated risks.
The full study was published in the journal BMJ Evidence-Based Medicine.
